Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curex
- Development stage
- Unknown
- Lead developer
- Boffin Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Curex Syrup** is a Boffin Biotech oral fixed-dose cough medicine. The Boffin-associated product listing identifies the active ingredients as guaifenesin, dextromethorphan hydrobromide, ammonium chloride, and CPM, interpreted as chlorpheniramine maleate. Its components provide expectorant, antitussive, and antihistamine effects for symptomatic cough relief. The product name is non-specific across the market, so this annotation is limited to the Boffin Biotech product. ([boffinbiotech.com](https://www.boffinbiotech.com/products.php))
- Brand names
- Curex
- Other names
- Curex Syrup
02
Targets
HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Curex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curex.